- Research article
- Open Access
- Open Peer Review
Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania
© Quentin et al; licensee BioMed Central Ltd. 2012
- Received: 2 June 2012
- Accepted: 13 November 2012
- Published: 13 November 2012
Cervical cancer is the leading cause of female cancer-related deaths in Tanzania. Vaccination against human papillomavirus (HPV) offers a new opportunity to control this disease. This study aimed to estimate the costs of a school-based HPV vaccination project in three districts in Mwanza Region (NCT ID: NCT01173900), Tanzania and to model incremental scaled-up costs of a regional vaccination program.
We first conducted a top-down cost analysis of the vaccination project, comparing observed costs of age-based (girls born in 1998) and class-based (class 6) vaccine delivery in a total of 134 primary schools. Based on the observed project costs, we then modeled incremental costs of a scaled-up vaccination program for Mwanza Region from the perspective of the Tanzanian government, assuming that HPV vaccines would be delivered through the Expanded Programme on Immunization (EPI).
Total economic project costs for delivering 3 doses of HPV vaccine to 4,211 girls were estimated at about US$349,400 (including a vaccine price of US$5 per dose). Costs per fully-immunized girl were lower for class-based delivery than for age-based delivery. Incremental economic scaled-up costs for class-based vaccination of 50,290 girls in Mwanza Region were estimated at US$1.3 million. Economic scaled-up costs per fully-immunized girl were US$26.41, including HPV vaccine at US$5 per dose. Excluding vaccine costs, vaccine could be delivered at an incremental economic cost of US$3.09 per dose and US$9.76 per fully-immunized girl. Financial scaled-up costs, excluding costs of the vaccine and salaries of existing staff were estimated at US$1.73 per dose.
Project costs of class-based vaccination were found to be below those of age-based vaccination because of more eligible girls being identified and higher vaccine uptake. We estimate that vaccine can be delivered at costs that would make HPV vaccination a very cost-effective intervention. Potentially, integrating HPV vaccine delivery with cost-effective school-based health interventions and a reduction of vaccine price below US$5 per dose would further reduce the costs per fully HPV-immunized girl.
- costs and cost analysis
- economics papillomavirus vaccines
- uterine cervical neoplasms
Cervical cancer is the second most frequent cancer in women worldwide . More than 80% of cervical cancers occur in developing countries . In Tanzania, as in much of sub-Saharan Africa, cervical cancer is the leading cause of female cancer deaths [3, 4]. Human papillomaviruses (HPV) are the etiological agents of cervical cancers , and vaccines against HPV (types 16 and 18) offer the opportunity to prevent about 70% of cervical cancer cases worldwide . Many high-income countries have national HPV vaccination programs , and Tanzania plans to start a national HPV vaccination program in late 2012 . Following the November 2011 decision of the Global Alliance for Vaccines and Immunisations (GAVI) to move towards funding HPV vaccines for eligible countries , HPV vaccination could become an option in many countries where HPV vaccines are currently unaffordable.
International studies have estimated that HPV vaccination of young girls would be cost effective in the 72 GAVI-eligible countries , and in Eastern Africa in particular , if the costs per vaccinated girl were between US$10 and US$25. However, preadolescent and adolescent schoolgirls, the target group for HPV vaccines, are not routinely included in most national immunization programs in sub-Saharan Africa. The costs of delivering HPV vaccines are therefore unknown . To plan for introducing HPV vaccines into national programs and to estimate cost effectiveness, governments and researchers need reliable estimates based on observed local costs.
This costing study was conducted as part of a project in Mwanza Region, Tanzania, which measured the feasibility, uptake, and acceptability of two alternative school-based HPV vaccine delivery strategies using a cluster randomized trial design (NCT ID: NCT01173900) . It aimed to analyze the observed costs of the school-based vaccination project and to explore cost differences between delivering vaccines to rural and urban schools and between the two alternative delivery strategies. It also aimed to estimate incremental costs of a scaled-up vaccination program for Mwanza Region and to calculate the associated costs per fully-immunized girl.
First, a top-down cost analysis of the school-based vaccination project was conducted from the project's perspective, using resource use and cost data collected alongside the cluster randomized trial. Second, based on the observed project costs, incremental costs of a scaled-up vaccination program for Mwanza Region were modeled from the perspective of the Tanzanian government, under the assumption that HPV vaccines would be delivered through the Expanded Programme on Immunization (EPI).
Study setting and intervention
The HPV vaccination project compared vaccine coverage in 134 primary schools randomly allocated to age-based (girls born in 1998) and class-based (class 6 of primary school in 2010) vaccine delivery in the two districts of Mwanza City and part of neighboring Misungwi district in northwest Tanzania. School-based vaccination was selected for the study because it has the best chance of achieving high coverage in Tanzania , where the government has a universal primary education policy and more than 80% of girls attend primary school (87% in urban regions, 80% in rural regions) . In 2010, about 26% of the Tanzanian population were estimated to be living in urban areas and urbanization was rapidly progressing with an annual urban population growth rate of 4.5% .
The project was carried out by the Mwanza Intervention Trials Unit (MITU) of the National Institute for Medical Research (NIMR), in collaboration with the London School of Hygiene and Tropical Medicine (LSHTM). (Additional file 1, Table S1 provides more details on the main activities of the intervention.) Ethical approval was obtained from the ethics committees of the Tanzanian Medical Research Coordinating Committee and the London School of Hygiene and Tropical Medicine. More details on consent procedures and refusal rates are presented in Watson-Jones et al.  and Remes et al. .
During the preparation phase, 242 schools were mapped and the number of girls in each was documented. Subsequently, 134 schools (60 rural and 74 urban) were randomly selected for vaccination, and then randomly allocated to either age-based or class-based vaccine delivery. Information about HPV vaccination was provided through school, parent and community meetings, leaflet and poster distribution, radio messages and community drama troupes. Two 2-day training sessions were held to train 84 health workers from 42 health facilities in cervical cancer, HPV vaccination, cold-chain logistics and in management and reporting of adverse events.
The quadrivalent (HPV 6, 11, 16 and 18) vaccine (Merck & Co.) was donated by Axios Healthcare Development, Cleveland, Ohio, USA (GARDASIL® Access Programme). The project covered costs of clearance and shipment of vaccines from arrival in Dar es Salaam to Mwanza. Vaccines were stored at MITU in three refrigerators under the supervision of a pharmacist. Between August 2010 and July 2011, eligible girls were offered three doses of vaccine during four vaccination rounds. On vaccination days, project vehicles took MITU supervisory nurses, EPI-trained nurses from health facilities that covered the selected schools, vaccines, and necessary supplies to the schools according to a prearranged timetable. After vaccination days, girls who missed vaccination at schools were given the opportunity to be vaccinated at health facilities during a window period of 2 to 4 weeks. At the end of the window, remaining vaccines were returned to MITU because of cold storage capacity constraints at the health facilities.
Materials used during vaccination were also returned to MITU and incinerated. International and local MITU staff were involved in administration, coordination and supervision of the project. All activities and project inputs related to research, including a proportion of the preparation costs, were excluded from the cost analysis (see Additional file 1, Table S1).
Data collection and analysis
Full financial and economic costs of running the project in 2010 and the first two quarters in 2011 were estimated using adapted versions of established costing guidelines [16, 17]. Financial costs represent actual expenditures on goods and services, while economic costs represent the economic value of all resources used including costs of goods and services that were not paid for by the project (for example, vaccines donated by Axios Healthcare Development).
Cost data were collected from the financial departments of the relevant institutions (MITU, NIMR, and LSHTM) by a researcher (WQ) during two visits to Mwanza in November 2010 and April 2011. Interviews were conducted with all relevant project staff members, as well as with regional and district EPI staff. Logbooks of project cars were evaluated to determine distances travelled. Vaccination of girls was observed by WQ during the second round of vaccination at four schools to record the time that nurses spent on vaccination activities at different types of school. During the third round of vaccination, MITU nurses recorded the time spent at schools and travel times between MITU, health facilities and schools for 40 schools. These data were complemented by time data recorded in logbooks of project cars to estimate the proportion of total time that MITU nurses spent for procurement and vaccination for each type of school (24% of total time for age-based urban, 22% for age-based rural, 28% for class-based urban, and 26% for class-based rural schools). In addition, vehicle logbooks were used to determine the proportion of total km travelled for delivering vaccines to rural and urban schools (75% and 25% of total km, respectively).
All cost data were distributed into five broad categories: (I) personnel, (II) other recurrent (including clinic consumables, communication, and so on), (III) allowances, (IV) transport, and (V) other capital costs for equipment. Annual capital costs were estimated based on replacement costs (for example, of comparable new vehicles or refrigerators) and assuming a life expectancy of 10 years for vehicles and refrigerators, and 5 years for other electronic equipment. Annual financial costs were calculated through straight-line depreciation, while annual economic costs were calculated using a 3% discount rate . An estimate of the average running cost per km of project cars (incl. driver salary, fuel, insurance, repairs) was available from the MITU financial department.
Costs of personnel were assigned to project activities based on staff estimates. Time inputs from government employees contributing to the project (that is, health facility nurses, teachers, other EPI staff) were included under economic costs. Other recurrent costs (for example, vaccination materials and allowances) could be directly attributed to the relevant activities based on information provided in the project management accounts. As vaccines were donated, financial costs exclude costs of the vaccine. Economic costs assume a price per dose of HPV vaccine of US$5 . In some cases, information from the principal investigator, MITU staff, or detailed financial records of the accounting department allowed assignment of costs. Transport costs were allocated to project activities on the basis of the km attributed to each project activity. Other capital costs for equipment (for example, refrigerators, cold boxes) could be directly attributed to relevant activities. Building costs and overheads (for example, housekeeping, water, and electricity except for refrigerators) were not considered.
Costs of training and social mobilization/information, education, communication (IEC) were treated as start-up costs and annuitized over 5 years. All cost data were adjusted to the year 2011 using country-specific GDP deflators , and were converted to US$ using average 2011 exchange rates .
Number of schools and girls (total and per school) by delivery strategy and school location in the Mwanza Vaccination Project and in a scaled-up regional program
Eligible girls (class 6, age 12)a
Average per school
Eligible girls (class 4, age 10)
Total number (estimated)c
Average per school
Incremental costs of a scaled-up regional vaccination program
A model was constructed in order to estimate the incremental financial and economic costs of a scaled-up vaccination program in Mwanza Region using an ingredients approach. Reflecting the plans of the Tanzanian government , the model estimates the additional costs of a class-based delivery program targeting girls in class 4 of primary school. Constructing the model involved two steps: first, quantities of necessary resources were estimated on the basis of experiences gathered during the school-based vaccination project, taking into account information from interviews with regional and district EPI staff about service delivery within routine EPI programs, statistics from the Ministry of Education and Vocational Training (MOEVT) , and assumptions from a WHO planning and costing tool for estimating costs of introducing HPV vaccines . (Additional file 1, Table S2 provides an overview of the cost categories, inputs included, and sources of information.) Second, unit costs or prices were assigned to the necessary inputs, using data from the analysis of project costs, the EPI comprehensive multi-year plan (CMYP) for Tanzania , and the WHO planning and costing tool . (A list of unit costs used in the model can be obtained from the authors upon request.)
Selected input parameters for modeling of a scaled-up vaccination program in Mwanza Region
Number of vaccination rounds
Capital discount rate
Refrigerators and cold rooms
Cold storage equipmenta
Additional vaccine distribution trips
Km per health facility per vaccination round, urban districts
Km per health facility per vaccination round, rural districts
Wastage rate (vaccines and materials)
Number of eligible girls per schoolb
Coverage ratesc for dose 1
Coverage ratesc for dose 2
Coverage ratesc for dose 3
Girls immunized in health facilities (%)
Vaccine clearance and shipment to regional level (costs/dose)
Base case assumptions usually reflect findings from the project cost analysis, interviews conducted with regional and district EPI staff, a standard discount rate , numbers of girls from MOEVT statistics, and, for economic costs, a price per dose of HPV vaccine of US$5 . Low cost assumptions assume only three vaccination rounds, a longer life expectancy of capital equipment as well as of sensitization and training, fewer additional or shorter distribution trips, higher coverage rates (as in existing EPI programs ), lower unit costs for the shipment of vaccines to the regional EPI office, and they exclude the costs of HPV vaccine. High cost assumptions use a discount rate as published by the Bank of Tanzania , shorter equipment life expectancies, and lower coverage rates.
Univariate and multivariate sensitivity analyses (SA) were carried out using the 'high cost' and 'low cost' assumptions. For the univariate sensitivity analysis, one model parameter was varied at a time with all other parameters kept constant. For the multivariate SA, all variables were simultaneously set to the 'low cost' assumptions or 'high cost' assumptions, respectively, in order to generate the largest possible range of costs in an analysis of extremes .
Analysis of project costs
Total project costs
Project costs per fully-immunized girl
Costs of a scaled-up regional vaccination program
Total program costs
Scaled-up class-based total costs of a human papillomavirus (HPV) vaccination program in Mwanza Region (in 2011 US$)*
1. Social mobilization/IEC (annuitized):
1.1. Meetings (teachers, parents/pupils)
1.2. Campaign (radio, cultural troops)
1.3. Material development
Subtotal social mobilization/IEC
2. Training (annuitized):
2.1. District staff training
2.2. Health facility staff training
2.3. Material development
3. Cold storage:
3.1. Regional level cold storage
3.2. District level cold storage
3.3. Health facility cold storage
Subtotal cold storage
4.1. Vaccines and supplies
4.2. Shipment to regional level
4.3. Transport to districts
4.4. Distribution to health facilities
5.1. School vaccination
5.2. Health facility vaccination
6. Waste management:
Subtotal waste management
6.1. Regional level supervision
6.2. District level supervision
Costs per fully-immunized girl and sensitivity analysis
Under base case assumptions for input parameters, the incremental economic scaled-up costs per fully-immunized girl through class-based delivery in Mwanza Region, including the cost of vaccine, were estimated at US$26.41. (Data for urban and rural schools and a comparison with project costs are presented in Additional file 1, Table S5 and Additional file 2, Figure S1.) The distribution of costs across program elements and the relationship between financial and economic costs mirrored the results presented in Table 3. Financial costs per fully-immunized girl, excluding costs of the vaccine and salaries of existing staff, were estimated at US$5.48 or US$1.73 per dose.
The World Health Organization recommends the inclusion of HPV vaccination in national immunization programs for girls 9 to 13 years old if (1) prevention of cervical cancer is a public health priority, (2) the introduction is programmatically feasible, (3) sustained financing can be secured, and (4) the cost effectiveness is considered . However, without detailed analyses of costs based on observed data collected in countries, it is impossible to reliably estimate cost effectiveness or to assess whether sustained financing will be available for HPV vaccination. In sub-Saharan Africa, where more than 1 million cancer cases could be averted through HPV vaccination of 10 consecutive birth cohorts of girls , empirical information about the delivery costs of vaccines to young adolescent girls was unavailable until very recently [11, 29].
This is one of the first studies to report detailed resource-use-based cost estimates for delivering HPV vaccines to schoolgirls in sub-Saharan Africa. Using data collected alongside a cluster randomized trial, our project cost analysis demonstrated large differences in the costs of delivering HPV vaccines to girls between age-based and class-based delivery. In addition, modeled costs of a scaled-up vaccination program for Mwanza Region in Tanzania showed that three doses of HPV vaccine, when excluding costs of the vaccine itself, could be delivered to girls at an incremental economic cost of US$3.09 per dose and about US$10 per fully-immunized girl. These estimates are similar to the US$3.15 per dose that have been reported by PATH and the national EPI program for a school-based HPV vaccination program in Uganda , but significantly higher than estimated for the costs of delivering new childhood vaccines (also excluding vaccine costs), such as pneumococcal or rotavirus vaccines in Kenya (US$1.06) , Uganda (US$0.34) , or Malawi (US$0.35) .
Our study has a number of limitations. First, despite our high reliance on observed data, the analysis of project costs was based on estimates and extrapolations for certain inputs. Personnel time was allocated to different activities of the intervention on the basis of staff interviews, which are a known source of uncertainty , although prospective time sheets (from the third round of vaccination), which are a better source of information, were used to allocate costs between procurement and vaccination. Vehicle logbooks were used for the allocation of transport costs but detailed records for the allocation between rural and urban schools were only consistently available for vaccination round three. However, these allocations would not be expected to change over time since the same schools were visited in each round. Furthermore, project costs are not representative of how much it would cost to deliver HPV vaccines within a national immunization program: the project delivered HPV vaccines through a vertical system specifically set up for the intervention. Such systems imply high costs for administration/supervision, transport, and a dedicated cold chain. Procurement costs in the project were particularly high for rural schools as vehicles always had to travel from Mwanza City to the rural district. In the scaled-up program, the difference in procurement costs between urban and rural schools was estimated to be much smaller as vaccines would be delivered from the district EPI office (see Additional file 2, Figure S1). In addition, salary costs of international staff accounted for about 18% of project costs (Figure 1). If they were replaced by their local equivalents, this would result in a reduction in total project costs by almost 20%.
Second, our scaled-up cost estimates, which aimed to overcome the problems of the project cost analysis by adjusting the costs for administration/supervision, transport and cold chain, have other limitations related to the adopted ingredients approach for modeling of costs. National level costs (such as administrative and supervision costs) were excluded, although these cost categories can be important; and the ingredients approach may underestimate inefficiencies. For example, for cold storage costs, the incremental costs of HPV vaccines were calculated as the costs of the additional volume required for storing the vaccines. However, if the introduction of HPV vaccines required an increase in the number of refrigerators or cold rooms, which would not be used during non-HPV-vaccination months, the incremental costs would be much higher. For cold storage, such a scenario was tested in the sensitivity analysis, which revealed that increasing the number of refrigerators in Mwanza Region to what district cold chain coordinators deemed necessary for adding HPV vaccination would increase the costs per fully-immunized girl by about 6%, that is, from US$26.41 to US$27.90 (Figure 3).
Third, our model calculated scaled-up costs based on experiences gathered over the course of the research project and adjusted observed costs based on assumptions derived from interviews with EPI staff in Mwanza City and Misungwi District. The model assumed that similarly high coverage rates would be achieved in a regional program as in the research project; that distances travelled from district stores to health facilities would be similar for all rural districts as those in Misungwi District; and that wastage rates of vaccines and materials would be similar to those in existing EPI programs . However, the influence of alternative assumptions was tested in sensitivity analyses (Figure 3), which showed that except for the unlikely case of the full worst case scenario, estimated costs would be relatively robust.
Despite these caveats, our research has major implications for policymakers and researchers. Firstly, in our project cost analysis, we found that costs per fully-immunized schoolgirl of delivering three doses of HPV vaccines using a class-based delivery strategy were about one-third below those of using age-based delivery, although the costs per school reached were not higher for age-based delivery (see Additional file 3, Figure S2). The reason for the lower costs per fully-immunized schoolgirl of class-based delivery in the project was the substantially higher number of girls vaccinated at class-based schools due to more eligible girls being identified and higher vaccine coverage (Table 1 and Watson-Jones et al. ). In a scaled-up regional program, which is likely to target a different group of girls (class 4 instead of class 6), the number of eligible girls per school would be similar under age-based and class-based delivery (Table 1). However, targeting a different age group may have further cost and effectiveness implications, which need to be considered. About 99% of girls in class 4 are in the target group for vaccination (between 9 and 13 years of age)  and are less likely to ever have had sex before [13, 34] than girls in class 6, where almost 20% are 13 years and older. However, as the full duration of protection offered by HPV vaccines still remains uncertain  (even if recent evidence has confirmed vaccine efficacy of 8.4 years  and modeling results suggest 20 years protection ), a trade off might exist between targeting girls early in life (prior to their sexual debut) and ensuring that they are still protected later in life. Furthermore, earlier vaccination implies a requirement for earlier booster doses, which may increase costs.
Secondly, we estimated scaled-up costs of US$26 per girl fully immunized against HPV. Even when excluding vaccine costs (see Figure 3), US$10 is required for delivering vaccines to schoolgirls. It is essential that these costs be adequately budgeted during vaccine introduction, in particular because a previous study found that system costs (social mobilization/IEC, training, cold storage, transport) were not covered by GAVI Alliance introduction grants during the introduction of DTwP-hepatitis B-HiB vaccine in Ethiopia . Furthermore, we found that the costs of a school-based vaccination program, when excluding costs of the vaccine, are mostly driven by the costs of reaching schools, for social mobilization/IEC, procurement and vaccination. Consequently, the marginal costs per fully HPV-immunized girl and social mobilization costs could potentially be reduced if HPV vaccines were delivered together with other school-based health interventions, such as tetanus toxoid (TT) vaccination, vitamin A supplementation or deworming with antihelminthics [29, 39] and/or reproductive health interventions. In addition, if recent findings are confirmed that two-dose HPV vaccine regimens may be effective for cervical cancer prevention , costs per fully-immunized girl can be expected to drop by about 30%.
Thirdly, our results should be incorporated into future cost-effectiveness analyses of HPV vaccines in Eastern Africa. Our model of a scaled-up regional HPV vaccination program estimated that costs per fully-immunized girl would be about US$26 (see Figure 3), when including a vaccine price of US$5 per dose . Results of existing cost-effectiveness studies [11, 41] suggest that HPV vaccination at US$25 per fully-immunized girl would be very cost effective in all countries of Eastern Africa: at US$25 purchasing power parities (PPP) per vaccinated girl, the costs per life-year saved (Campos et al. ) or per disability adjusted life-year (DALY) averted (Kim et al. ) would be below the per capita income in these countries. Of course, if HPV vaccine prices drop below US$5 and vaccines are delivered together with other school-based health interventions (see above), cost effectiveness would further increase. Currently, the GAVI decision to support the introduction of HPV vaccines in developing countries  and the donation offer to the Tanzanian government of 2 million doses of HPV vaccine  present an unprecedented opportunity for the introduction of this life-saving intervention.
The introduction of HPV vaccination in sub-Saharan Africa offers a new opportunity for cervical cancer control. Our cost estimates suggest that the vaccine can be delivered at costs that would make HPV vaccination a very cost-effective intervention . Potentially, delivering HPV vaccines together with other cost-effective school-based health interventions and a reduction of the vaccine price below US$5 per dose would lead to lower costs and higher cost effectiveness. Furthermore, if two-dose HPV vaccine regimens were effective for cervical cancer prevention , costs per fully-immunized girl would drop by about 30%.
We thank Riziki Ponsiano, Stephen Makandilo, Ramadhan Hashim, Francesca Lemme, Kathy Baisley, the HPV mapping and vaccine teams at NIMR/MITU and participating EPI nurses and teachers in Mwanza. We are grateful to Jacqueline Jackson, Tamara Hurst and Eleanor Martins for administrative support. HPV vaccine from Axios Healthcare Development was donated through the GARDASIL® Access Program. This work was supported by the World Health Organization (WHO Reference 2010/103980-1), the Wellcome Trust (grant no. WT090318MA) and a Cervical Cancer Initiative grant from the Union of International Cancer Control (UICC). The funding agencies had no involvement in the design, data collection, analysis or interpretation of the results. RHu is a staff member of the World Health Organization. The views expressed are those of the author and do not necessarily represent the views of the World Health Organization. DW-J has received grant support through her institution from GlaxoSmithKline Biologicals. WJE's partner works for GlaxoSmithKline. There are no other conflicts of interest. The results from this study have been presented in part at the 27th International Papillomavirus Conference, Berlin, 17 to 22 September 2011 (Quentin W, Watson-Jones D, Changalucha J, et al. Costs of delivering HPV vaccine to schoolgirls in Tanzania. (Abstract O 05.05).
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.View ArticlePubMedGoogle Scholar
- Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine. 2006, 24 (Suppl 3): 3-11.Google Scholar
- WHO/ICO: Human Papillomavirus and Related Cancers. Summary report update for Tanzania. 2010, Barcelona, Spain: WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre)Google Scholar
- Ferlay J, Shin HR, Bray F, Forman D, Mathers CD, Parkin DM: Globocan 2008 v 1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2010, Lyon, France: International Agency for Research on CancerGoogle Scholar
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Frazer IH: HPV vaccines and the prevention of cervical cancer. Update Cancer Therapeutics. 2008, 3: 43-48. 10.1016/j.uct.2008.02.002.View ArticleGoogle Scholar
- Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, Panatto D, Gasparini R, Boccalini S: An overview on the implementation of HPV vaccination in Europe. Hum Vaccin. 2009, 7: 128-135.View ArticleGoogle Scholar
- Tanzania Ministry of Health and Social Welfare: Expanded Programme on Immunization 2010 - 2015 Comprehensive Multi Year Plan. 2011, Dar es Salaam, Tanzania: The United Republic of Tanzania, Ministry of Health and Social Welfare (MOHSW)Google Scholar
- GAVI: HPV Factsheet. 2011, Geneva, Switzerland: Global AllianceGoogle Scholar
- Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim S: Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008, 26: 4080-4093. 10.1016/j.vaccine.2008.04.053.View ArticlePubMedGoogle Scholar
- Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, Goldie SJ: Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer. 2012, 130: 2672-2684. 10.1002/ijc.26269.View ArticlePubMedGoogle Scholar
- Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, Sanjose S de, Wight D, Changalucha J, Hayes R: Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis. 2012, 206: 678-686. 10.1093/infdis/jis407.View ArticlePubMedPubMed CentralGoogle Scholar
- National Bureau of Statistics (NBS) and ICF Macro: Tanzania Demographic and Health Survey 2010. 2011, Dar es Salaam, Tanzania: NBSGoogle Scholar
- UNICEF: Statistics for the United Republic of Tanzania. [http://www.unicef.org/infobycountry/tanzania_statistics.html]
- Remes P, Selestine V, Changalucha J, Ross DA, Wight D, de Sanjosé S, Kapiga S, Hayes RJ, Watson-Jones D: A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine. 2012, 30: 5363-5367. 10.1016/j.vaccine.2012.06.025.View ArticlePubMedPubMed CentralGoogle Scholar
- WHO: Guidelines for estimating costs of introducing new vaccines into the national immunization system. 2002, Geneva, Switzerland: World Health Organisation (WHO)Google Scholar
- UNAIDS: Costing guidelines for HIV prvention strategies. 2000, Geneva, Switzerland: Joint United Nations Program on HIV/AIDS (UNAIDS)Google Scholar
- Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL: Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. 2003, Geneva, Switzerland: World Health Organization (WHO)Google Scholar
- UICC: UICC welcomes commitment to lower prices for HPV vaccines. [http://www.uicc.org/programmes/uicc-welcomes-commitment-lower-prices-hpv-vaccines]
- IMF: World Economic Outlook Database. Selected Indicators for Tanzania and the United States. 2011, Washington, DC: International Monetary Fund (IMF)Google Scholar
- OANDA: Historical exchange rates. [http://www.oanda.com/currency/historical-rates/]
- MOEVT: Basic Statistics in Education - Regional 2010. 2011, Dar es Salaam, Tanzania: Ministry of Education and Vocational Training (MOEVT)Google Scholar
- Hutubessy R, Levin A, Wang S, Morgan W, Ally M, Broutet N, John T: Costing nationwide HPV vaccine delivery in Low and Middle Income Countries using the WHO Cervical Cancer Prevention and Control Costing Tool: A case study of The United Republic of Tanzania. BMC Med. 2012Google Scholar
- WHO: Immunization Profile - United Republic of Tanzania. 2012, Geneva, Switzerland: World Health Organization (WHO)Google Scholar
- BOT: Monthly Economic Review June 2010. 2010, Dar es Salaam, Tanzania: Bank of Tanzania (BOT)Google Scholar
- Briggs A, Sculpher M, Buxton M: Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994, 3: 95-104. 10.1002/hec.4730030206.View ArticlePubMedGoogle Scholar
- WHO: Human papillomavirus vaccines WHO position paper. Wkly Epidemiolog Rec. 2009, 84: 118-131.Google Scholar
- Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY: Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008, 26: 4080-4093. 10.1016/j.vaccine.2008.04.053.View ArticlePubMedGoogle Scholar
- PATH, Uganda National Expanded Programme on Immunisation (UNEPI), Child Health and Development Centre (CHDC): HPV Vaccine Demonstration Project in Uganda: Results, Lessons Learnt, and Recommendations. 2010, Seattle, WA: PATHGoogle Scholar
- Tate JE, Rheingans RD, O'Reilly CE, Obonyo B, Burton DC, Tornheim JA, Adazu K, Jaron P, Ochieng B, Kerin T, Calhoun L, Hamel M, Laserson K, Breiman RF, Feikin DR, Mintz ED, Widdowson M: Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis. 2009, 200 (Suppl 1): S76-84.View ArticlePubMedGoogle Scholar
- Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F: Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine. 2011, 29: 3329-3334. 10.1016/j.vaccine.2010.12.122.View ArticlePubMedGoogle Scholar
- Berry SA, Johns B, Shih C, Berry AA, Walker DG: The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis. 2010, 202: S108-15. 10.1086/653578.View ArticlePubMedPubMed CentralGoogle Scholar
- Bratt JH, Foreit J, Chen PL, West C, Janowitz B, Vargas T de: A comparison of four approaches for measuring clinician time use. Health Policy Plan. 1999, 14: 374-381. 10.1093/heapol/14.4.374.View ArticlePubMedGoogle Scholar
- Zaba B, Isingo R, Wringe A, Marston M, Slaymaker E, Urassa M: Influence of timing of sexual debut and first marriage on sexual behaviour in later life: findings from four survey rounds in the Kisesa cohort in northern Tanzania. Sex Trans Infect. 2009, 85: i20-10.1136/sti.2008.033704.View ArticleGoogle Scholar
- Romanowski B: Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin. 2011, 7: 161-169. 10.4161/hv.7.2.13690.View ArticlePubMedGoogle Scholar
- Roteli-Martins C, Naud P, Borba P de, Teixeira J, Carvalho N de, Zahaf T, Sanchez N, Geeraerts B, Descamps D: Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012, 8.Google Scholar
- David M, van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, van Damme P: Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Cervical Cancer Vaccines: The Role of the Immunological Profile and Future Expectations for Vaccination II. Gynecol Oncol. 2009, 115: S1-10.1016/j.ygyno.2009.01.011.View ArticlePubMedGoogle Scholar
- Griffiths UK, Korczak VS, Ayalew D, Yigzaw A: Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine. 2009, 27: 1426-1432. 10.1016/j.vaccine.2008.12.037.View ArticlePubMedGoogle Scholar
- Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, Kaipilyawar S, Gandhi S: Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine. 2009, 27: 6203-6209. 10.1016/j.vaccine.2009.08.003.View ArticlePubMedGoogle Scholar
- Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S: Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011, 103: 1444-1451. 10.1093/jnci/djr319.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim S, Sweet S, Chang J, Goldie SJ: Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis. 2011, 11: 174-10.1186/1471-2334-11-174.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/10/137/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.